Your browser doesn't support javascript.
loading
A Neutral and Stable Macrocyclic Mn(II) Complex for MRI Tumor Visualization.
Leone, Loredana; Anemone, Annasofia; Carella, Antonella; Botto, Elena; Longo, Dario Livio; Tei, Lorenzo.
Afiliação
  • Leone L; Department Science and Technological Innovation, University of Piemonte Orientale, Viale Teresa Michel 11, 15121, Alessandria, Italy.
  • Anemone A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza, 52, 10126, Torino, Italy.
  • Carella A; Institute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), Via Nizza, 52, 10126, Torino, Italy.
  • Botto E; Institute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), Via Nizza, 52, 10126, Torino, Italy.
  • Longo DL; Institute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), Via Nizza, 52, 10126, Torino, Italy.
  • Tei L; Department Science and Technological Innovation, University of Piemonte Orientale, Viale Teresa Michel 11, 15121, Alessandria, Italy.
ChemMedChem ; 17(24): e202200508, 2022 12 16.
Article em En | MEDLINE | ID: mdl-36198652
ABSTRACT
A stable and inert amphiphilic Mn(II) complex based on a bisamide derivative of 1,4-DO2A (DO2A=tetraazacyclododecane-1,4-diacetic acid) was synthesized and its 1 H NMR relaxometric behavior was investigated as a function of the magnetic field strength, pH and temperature. The interaction with human serum albumin (HSA) was also studied via relaxometry showing a good relaxivity enhancement at low field (at 1T and 298 K the relaxivity increases from 4.5 mM-1 s-1 of the Mn(II)-complex to 14.0 mM-1 s-1 of the complex-HSA supramolecular adduct). In vivo biodistribution and MRI studies highlighted a rapid and mixed renal/liver elimination without spleen accumulation from healthy mice and good contrast enhancing properties in a breast tumor murine model. A comparison with a clinically approved Gd(III) agent (GdBOPTA, Multihance®) underlined that the proposed Mn(II) contrast agent gave comparable tumor contrast enhancement up to 3 hours post-injection.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Meios de Contraste / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Meios de Contraste / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article